The LRIG family: enigmatic regulators of growth factor receptor signaling

Catalina Simion, Maria Elvira Cedano-Prieto and Colleen Sweeney

Department of Biochemistry and Molecular Medicine, University of California Davis School of Medicine, 4645 2nd Avenue, Sacramento, California 95817, USA

Correspondence should be addressed to C Sweeney
Email casweeney@ucdavis.edu

Abstract

The leucine-rich repeats and immunoglobulin-like domains (LRIG) family of transmembrane proteins contains three vertebrate members (LRIG1, LRIG2 and LRIG3) and one member each in flies (Lambik) and worms (Sma-10). LRIGs have stepped into the spotlight as essential regulators of growth factor receptors, including receptor tyrosine and serine/threonine kinases. LRIGs have been found to both negatively (LRIG1 and LRIG3) and positively (Sma-10 and LRIG3) regulate growth factor receptor expression and signaling, although the precise molecular mechanisms by which LRIGs function are not yet understood. The most is known about LRIG1, which was recently demonstrated to be a tumor suppressor. Indeed, in vivo experiments reinforce the essential link between LRIG1 and repression of its targets for tissue homeostasis. LRIG1 has also been identified as a stem cell marker and regulator of stem cell quiescence in a variety of tissues, discussed within. Comparably, less is known about LRIG2 and LRIG3, although studies to date suggest that their functions are largely distinct from that of LRIG1 and that they likely do not serve as growth/tumor suppressors. Finally, the translational applications of expressing soluble forms of LRIG1 in LRIG1-deficient tumors are being explored and hold tremendous promise.

Key Words
- LRIG1
- LRIG2
- LRIG3
- growth factor receptor
- tumor suppressor
- stem cell

Introduction

The members of the leucine-rich and immunoglobulin-like domains family of proteins (LRIGs) are single-pass transmembrane proteins implicated in the regulation of growth factor receptors. There is one Lrig gene in flies (lambik, www.flybase.org) and worms (sma-10, Gumienny et al. 2010) and three in vertebrates (LRIG1, LRIG2, and LRIG3). The LRIG proteins contain tandem leucine-rich repeats followed by three immunoglobulin-like domains, a transmembrane domain and a large cytoplasmic tail (Fig. 1). LRIGs show homology in their extracellular domains and also in the juxtamembrane portion of their cytoplasmic domains. The remainder of the cytoplasmic domain diverges significantly amongst LRIGs (Abraira et al. 2010) and may impart unique functions.

LRIGs are broadly expressed in healthy human tissue and LRIG transcripts have been detected in at least 26 distinct tissue types with significant variation in relative abundance amongst the LRIGs (Guo et al. 2004). The human LRIG1 gene is located at chromosome 3p14.3 (Nilsson et al. 2001), LRIG2 at chromosome 1p13 (Holmlund et al. 2004), and LRIG3 at 12q13.2 (Guo et al. 2004). 3p14 and 1p13 are chromosomal regions known to be frequently deleted in cancer, while 12q13 has been reported to be amplified in glioblastoma (Reifenberger et al. 1996, Mischel et al. 2003). 12q13 is also identified...
disorder characterized by a severe dysfunction in urinary bladder voiding. Patients also display a telltale facial grimace when attempting to smile (Bacchetta & Cochat 2010). In 2010, biallelic loss of function mutations in Heparanase-2 (HPSE2) were identified as causative for UFS (Daly et al. 2010, Pang et al. 2010). Heparanase-2 inhibits Heparanase-1 (HPSE1) which in turn regulates the availability and signaling of growth factors through processing of heparan sulfate proteoglycans (which sequencer growth factors). As HPSE2-linked UFS and LRIG2-linked UFS are reported to be clinically indistinguishable, it has been proposed that HPSE2 and LRIG2 functions overlap and that their functional loss may lead to aberrant growth factor receptor signaling (Roberts et al. 2014). Of note, LRIG2 and HPSE2 proteins are co-expressed in human fetal bladder and have been immuno-localized to nerve fascicles growing into the bladder wall, raising the possibility of peripheral nerve involvement in UFS (Daly et al. 2010, Stuart et al. 2013). In direct support of this, recent studies in Xenopus have revealed that xHPSE2 depletion leads to up-regulated FGF2 signaling and perturbed motor neuron development (Roberts et al. 2014).

LRIG3 is required for neural crest formation in Xenopus, a process driven by a balance of FGF, BMP, and canonical WNT signaling (Zhao et al. 2008). In experiments using antisense oligos to reduce the expression of endogenous Lrig3, LRIG3 was found to be required for the induction of neural crest markers including SLUG, TWIST, FOXD3, and SOX9. At the receptor level, Lrig3 was found to enhance canonical WNT signaling but inhibit FGF signaling, in both animal caps and human HEK-293T cells. LRIG3 interacted with and decreased the expression of Xenopus FGFR1, providing a plausible mechanism by which LRIG3 attenuates FGF signaling, but the mechanism by which LRIG3 potentiates WNT signaling is not known.

Sma-10, the sole Caenorhabditis elegans LRIG, is required for body size regulation, with Sma-10 mutant worms smaller than wild type worms (Gumienny et al. 2010). Lambik, the sole Drosophila LRIG, rescues the body size phenotype in Sma-10 mutants, demonstrating evolutionary conservation of function. However, nothing else is known regarding Lambik. In reporter assays in human HepG2 hepatocellular carcinoma cells, Sma-10 was found to promote bone morphogenetic protein (BMP) signaling. BMPs signal through receptor serine/threonine kinases and ligands and receptors belong to the TGFβ/TGFβ-receptor superfamily. In co-precipitation assays in human embryonic kidney 293T cells, Sma-10 was found to interact with the BMP receptors SMA6 and
DAF4, type I and type II receptors respectively. LRIG1 was also found to interact with type I receptors including ALK6, ALK1, ALK2 and ALK3 and ACTR1B and type II receptors including ACTR2 and ACTR2B. However, the functional impact of LRIG1 (positive or negative?) on BMP signaling is unknown. As LRIG3 is the only mammalian LRIG shown (thus far) to enhance expression of some of its interacting partners, it is tempting to speculate that LRIG3, rather than LRIG1, is the mammalian LRIG which regulates BMP signaling.

LRIG expression in cancer

LRIG1 was cloned from mouse brain in 1996 (Suzuki et al. 1996) and from human brain in 2001 (Nilsson et al. 2001). Its expression in cancer has been a topic of interest for more than a decade, since Hedman et al. (2002) first proposed that LRIG1 is a tumor suppressor and negative regulator of EGF receptor signaling. LRIG1 expression in cancer has been widely examined and of note, LRIG1 recently emerged as one of four genes with prognostic impact in melanoma, glioma, and cancers of breast, bladder, and lung. In eight independent cohorts representing these cancers, a decrease in LRIG1 expression was associated with worse patient prognosis (Rouam et al. 2010).

LRIG1 expression is decreased relative to normal tissue in most, but not all, cancer types examined to date (reviewed in Hedman & Henriksson (2007) and Wang et al. (2013)). With recent advancements in genome-wide analysis of human tumors, tumor subtype has become an accessible variable to consider in the analysis of cancer-relevant genes. With respect to LRIG1, differences in expression amongst tumor subtypes, both conventional histological subtypes and molecular-based subtypes, are evident. For example, LRIG1 mRNA expression is decreased in clear-cell renal-cell carcinoma (relative to normal kidney cortex) but not in papillary or chromophobe renal cell carcinomas (Thomasson et al. 2012).

In prostate and breast cancer, LRIG1 expression is induced by androgen and estrogen respectively. High LRIG1 expression observed in hormone receptor-positive disease is likely a reflection of transcriptional activation of the LRIG1 gene by androgen/estrogen receptors (Krig et al. 2011, Thomasson et al. 2011). Indeed, LRIG1 mRNA is enriched in the luminal subtypes of breast cancer (estrogen receptor-positive) but is weakly expressed in the Her2-enriched, basal-like, and claudin-low subtypes (mostly estrogen receptor-negative) (Miller et al. 2008, Wang et al. 2013). Despite high expression, in vitro experiments have demonstrated that LRIG1 plays a growth inhibitory role in both prostate and breast cancer cells (Laederich et al. 2004, Krig et al. 2011, Thomasson et al. 2011). In agreement with this, intermediate/high LRIG1 mRNA expression was found to correlate with prolonged relapse-free survival in estrogen receptor-positive breast cancer (Krig et al. 2011). More recently, LRIG1 gene copy number was examined in a large cohort of early-stage (I/II) breast cancers (Thompson et al. 2014). The copy number losses were found to be more common in triple-negative and Her2-positive breast cancer when compared with luminal breast cancer, in agreement with weak expression of LRIG1 in these subtypes. Importantly, LRIG1 copy number loss was strongly associated with an elevated and persistent risk of recurrence, distant metastasis, and overall mortality. This study also examined LRIG1 mRNA expression across 18 publicly available datasets and revealed that, as with copy number loss, low LRIG1 mRNA expression is significantly and persistently correlated with shorter distant metastasis-free and overall survival. These notable findings highlight the potential utility of clinically assessing LRIG1 expression for patient risk stratification and also implicate LRIG1 in restricting cellular behaviors fundamental to breast cancer metastasis, such as motility and invasion.

In prostate cancer, the relationship between LRIG1 expression and patient outcome may be more complex. In a US cohort of patients who underwent radical prostatectomy, high LRIG1 expression was found to correlate with prolonged overall survival. However, the authors noted that prostate cancer-specific survival information was not available for this cohort and that most of the deaths annotated by overall survival were not likely due to prostate cancer. Conversely, in an independent Swedish cohort who was followed by watchful waiting, high LRIG1 expression was found to correlate with decreased prostate cancer-specific and overall survival. Given the discussed limitations of assessing overall survival, more confidence may be placed in the results from the Swedish cohort, although further study is necessary. While LRIG1 inhibits the growth of cultured prostate cancer cells, as a transcriptional target of androgen receptor, its expression in prostate tumors may reflect robust androgen receptor signaling and indicate poor prognosis (Thomasson et al. 2011).

In addition to the tumor types/subtypes discussed above, high LRIG1 expression has been linked to good prognosis in squamous cell carcinoma of the skin (Tanemura et al. 2005), cervical adenocarcinoma (Muller et al. 2013), oropharyngeal cancer (Lindquist et al. 2014), and nasopharyngeal cancer (NPC; Sheu et al. 2014).
In NPC, LRIG1 and phospho-EGFR staining were inversely correlated in primary tumor specimens and ectopic expression of LRIG1 in cultured NPC cells led to the transcriptional down-regulation of EGFR/ERBB-activating ligands, providing one mechanism by which LRIG1 inhibits receptor phosphorylation. In both cervical adenocarcinoma and oropharyngeal cancer, LRIG1 expression correlates with positive HPV status and in oropharyngeal cancer, HPV-positive tumors with high LRIG1 expression show particularly good prognosis. In oral squamous cell carcinomas, LRIG1 expression is decreased relative to healthy oral mucosa, particularly in poorly differentiated tumors (Jensen et al. 2008, Sheu et al. 2014). This link to tumor differentiation was also observed in squamous cell carcinoma of the skin (Tanemura et al. 2005) and led the authors to propose that LRIG1 deletion may lead to tumor de-differentiation. In astrocytoma, LRIG1 mRNA is decreased compared with non-neoplastic tissue (Ye et al. 2009). In lung cancer, LRIG1 mRNA and protein was found to be decreased in 100% (10/10) of carcinoma in situ (CIS) specimens compared with matched normal airway, with an associated increase in EGFR expression (Lu et al. 2013). Four of these ten CIS specimens showed loss of heterozygosity (LOH) of the LRIG1 locus. Moreover, 75% of 138 lung cancer cell lines and 76% of 37 squamous cell carcinoma cell lines showed LOH of the LRIG1 locus. In a small cohort of malignant ocular surface squamous neoplasias, LRIG1 protein expression was found to be decreased compared with normal and benign tissues (where LRIG1 was overexpressed) and was found to inversely correlate with EGFR expression (Nagata et al. 2014). LRIG1 down-regulation may have potential as a marker of malignancy in a tumor type which completely lacks molecular markers.

Much less is known regarding LRIG2 and LRIG3 expression in cancer and available evidence indicates tissue-specific differences as well as differences dependent upon LRIG subcellular localization. In cervical adenocarcinoma, a high fraction of LRIG3-positive cells correlates with prolonged survival, as observed for LRIG1 (Muller et al. 2013). Peri-nuclear staining of LRIG2 and LRIG3 in diffusely infiltrating astrocytomas was found to correlate with better survival, with LRIG3 emerging as an independent prognostic factor (Guo et al. 2006). The significance of LRIG peri-nuclear localization is not presently understood and the identities of the cellular compartments to which LRIGs localize are unknown although it has been postulated that they may represent endosomes and/or trans-Golgi vesicles (Hedman & Henriksson 2007). It should be noted that the localization patterns of LRIGs vary significantly, in a cell- and tissue-specific manner, and nuclear (Karlsson et al. 2008, Muller et al. 2013, Lindquist et al. 2014), peri-nuclear (Guo et al. 2006), cytoplasmic (Holmlund et al. 2009, Muller et al. 2013), and cell surface localizations have been observed (Laederich et al. 2004). Interestingly, cytoplasmic LRIG2 expression was found to be an independent prognostic factor associated with decreased survival in an oligodendroglioma cohort (Holmlund et al. 2009). Similarly, in early stage squamous cervical carcinoma, cytoplasmic LRIG2 staining was linked to poor survival and identified as an independent prognostic factor while LRIG1 expression was associated with favorable outcome (Hedman et al. 2010). In non-small cell lung cancer, LRIG2 mRNA and protein expression were found to be decreased compared with adjacent tissue. Here again, high cytoplasmic staining of LRIG2 was found to be an independent predictor of poor 5 year survival (Wang et al. 2014).

The publicly accessible cBioPortal for cancer genomics (cbioportal.org, Cerami et al. 2012, Gao et al. 2013) contains 69 cancer genomics studies derived from 17 087 (to date) unique tumor samples. Analysis of LRIG profiles in cBioPortal reveals that LRIG genes are altered in cancer (mutation, deletion, amplification) with distinct overall patterns. For example, gene amplification makes up a greater percentage of LRIG3 alterations, relative to LRIG1 and LRIG2, while most of the LRIG1 and LRIG2 alterations are mutations. Mutation Assessor (available at cbioPortal, Reva et al. 2011) categorizes mutations into those predicted to have high, medium, low and no functional impact based on evolutionary conservation patterns. LRIG mutations with a high impact score according to Mutation Assessor are shown in Table 1. High impact mutations are localized exclusively to the extracellular domain which is not unexpected given the conservation of this region of LRIGs and the requirement of the extracellular domain for the recognition of interacting partners (Gur et al. 2004, Rafidi et al. 2013).

**Knowledge gained from LRIG mouse models**

* Lrig1 in the skin

The first study of a Lrig-knockout (KO) mouse was published in 2002 by Itami's group at Osaka University (Suzuki et al. 2002). On a mixed (129S7/SvEV and C57BL/6) background, Lrig1-KO mice (neo/neo) developed psoriasisform lesions with epidermal hyperplasia on the tail, face, and ears. Lrig1-null keratinocytes were hyperproliferative and demonstrated perturbed terminal
differentiation. This study also revealed that LRIG1 is down-regulated in psoriatic human skin. However, a subsequent study found no down-regulation of LRIG1 mRNA or protein but did reveal changes in cellular and subcellular distribution of the LRIG proteins in psoriatic skin compared with normal skin (Karlsson et al. 2008). Thus, changes in subcellular localization of LRIGs have been observed in both cancer and psoriasis, although as discussed, the significance of these changes is not understood.

The work by Suzuki et al. set the stage for subsequent studies from Jensen, Watt et al. which identified LRIG1 as an epidermal stem cell marker and regulator of stem cell quiescence. Overexpression of LRIG1 was found to reduce human keratinocyte proliferation and EGFR responsiveness through downregulation of EGFR, while keratinocytes in which LRIG1 was depleted had elevated surface EGFR, reinforcing the role of LRIG1 as an essential ERBB negative regulator. Furthermore, LRIG1 depletion resulted in epidermal stem cell expansion (Jensen & Watt 2006). Analysis of Lrig1-KO mice has provided unique insight into the role of LRIG1 in epidermal homeostasis (Jensen et al. 2009). Paradoxically, LRIG1-positive epidermal stem cells are highly proliferative (Page et al. 2013). Interestingly, this high proliferation index is also observed in one study of LRIG1-positive intestinal stem cells (Wong et al. 2012). LRIG1-positive epidermal stem cells are responsible for the maintenance of the upper pilosebaceous unit and contribute separately to the infundibulum and the sebaceous gland, such that any one LRIG1-positive stem cell contributes to either compartment but not both. The expression of oncogenic K-Ras (G12D) in LRIG1-positive cells is sufficient to drive infundibula and sebaceous gland hyperplasia but tumors are only observed when K-Ras expression is combined with full-thickness wounding.

### Table 1  LRIG mutations in human malignancy

<table>
<thead>
<tr>
<th>LRIG1</th>
<th>LRIG2</th>
<th>LRIG3</th>
</tr>
</thead>
<tbody>
<tr>
<td>N102I, cutaneous melanoma, LRRs</td>
<td>N297S, lung adenocarcinoma, LRRs</td>
<td>N585Y, hepatocellular carcinoma, Ig-like</td>
</tr>
<tr>
<td>L1045, endometrial carcinoma, LRRs</td>
<td>N584D, stomach adenocarcinoma, Ig-like</td>
<td><em>P726R</em>, bladder urothelial carcinoma, Ig-like</td>
</tr>
<tr>
<td>L146R, stomach adenocarcinoma, LRRs</td>
<td>L591Y, endometrial carcinoma, Ig-like</td>
<td></td>
</tr>
<tr>
<td>N198H, endometrial carcinoma, LRRs</td>
<td>C623Y, cutaneous melanoma, Ig-like</td>
<td></td>
</tr>
<tr>
<td>L213P, stomach adenocarcinoma, LRRs</td>
<td>P723T, pancreatic adenocarcinoma, Ig-like</td>
<td></td>
</tr>
<tr>
<td>L389P, lung squamous cell carcinoma, LRRs</td>
<td>G718R, cutaneous melanoma, Ig-like</td>
<td></td>
</tr>
<tr>
<td>V595M, endometrial carcinoma, Ig-like</td>
<td>P626Q, lung adenocarcinoma, Ig-like</td>
<td></td>
</tr>
<tr>
<td>L432F, cutaneous melanoma, LRRs</td>
<td>G770D, colorectal, Ig-like</td>
<td></td>
</tr>
<tr>
<td>G770D, colorectal, Ig-like</td>
<td>L146R, stomach adenocarcinoma, LRRs</td>
<td></td>
</tr>
<tr>
<td>N198H, endometrial carcinoma, LRRs</td>
<td>N495S, endometrial carcinoma, LRRs</td>
<td></td>
</tr>
<tr>
<td>S591Y, cutaneous melanoma, Ig-like</td>
<td>N585Y, hepatocellular carcinoma, Ig-like</td>
<td></td>
</tr>
<tr>
<td>L104S, endometrial carcinoma, LRRs</td>
<td><em>N102I</em>, cutaneous melanoma, LRRs</td>
<td></td>
</tr>
<tr>
<td>N584D, stomach adenocarcinoma, Ig-like</td>
<td>N297S, lung adenocarcinoma, LRRs</td>
<td></td>
</tr>
<tr>
<td>N585Y, hepatocellular carcinoma, Ig-like</td>
<td>L104S, endometrial carcinoma, LRRs</td>
<td></td>
</tr>
<tr>
<td>P723T, pancreatic adenocarcinoma, Ig-like</td>
<td>N584D, stomach adenocarcinoma, LRRs</td>
<td></td>
</tr>
</tbody>
</table>

LRIG mutations identified in human tumors which are predicted to have a high functional impact. Mutations collated at cbioportal.org and functional impact according to Mutation Assessor, also available at cbioportal.org.

### Lrig1 in the intestine

A major advance in the LRIG field came with the first in vivo evidence that LRIG1 is a tumor suppressor (Powell et al. 2012). At 5–6 months of age, Lrig1-null mice (CreERT2/CreERT2) were shown to develop highly penetrant duodenal adenomas with increased expression of EGFR, ERBB2, and ERBB3, providing significant in vivo evidence of LRIG1’s role as a negative regulator of ERBB receptors. This study also examined the expression of Lrig1 in intestinal stem cells. Lineage tracing in Lrig1 ‘reporter mice’ (in which β-galactosidase activity reports where endogenous LRIG1 is transcribed) revealed labeling of the base of crypts in both small intestine and colon. Over time, crypts turned completely (and persistently) blue and were populated with an array of differentiated cells, providing unequivocal evidence that LRIG1 marks intestinal stem cells. Endogenous LRIG1 protein expression was also detected with immunostaining and FACS. LRIG1-positive stem cells were relatively quiescent with a lower proliferative index than leucine-rich repeat containing G-protein coupled receptor-5 (LGR5)-positive stem cells. LRIG1- and LGR5-positive stem cells also diverged at the level of their transcriptomes with LRIG1-positive cells showing the evidence of cell cycle repression. However, upon irradiation injury, LRIG1-positive stem cells proliferated and repopulated damaged crypts.

In a simultaneously published study from Jensen’s group, LRIG1 was also found highly enriched in intestinal and colonic stem cells (Wong et al. 2012). However, in this study, LRIG1 and LGR5 positivity overlapped and most LRIG1-positive cells were proliferative as measured by 5-bromodeoxyuridine (BrdU) uptake. Notably, Lrig1-null mice (Suzuki et al. 2002, neo/neo) crossed into the FvB background displayed grossly enlarged abdomens,
necessitating their being killed at post-natal day 10. The size of intestinal crypts in these mice was dramatically increased and the crypts contained more proliferating cells. Flow cytometry revealed the expansion of the CD24low/mid/UEA1-negative stem/progenitor population. In Lrig1-null intestinal epithelium, there was a substantial increase in the protein (but not transcript) levels of EGFR, ERBB2, ERBB3, and the MET receptor as well as an increase in the phosphorylation of EGFR/ERBB2/ERBB3, herein again emphasizing the essential in vivo role of Lrig1 as a negative regulator of growth factor receptors. 

In support of this, daily administration of Gefitinib, an EGFR inhibitor, decreased EGFR phosphorylation and restored crypt size and proliferation to that of wild-type levels. Furthermore, the Lrig1-null phenotype was rescued (in ~40% of mice) by crossing with heterozygous Egfrwa2 mice, an Egfr hypomorph (Luetteke et al. 1994).

Recently, Powell et al. (2014) have reported the development of a superior mouse model of familial adenomatous polyposis (FAP). FAP arises from germline mutations in the adenomatous polyposis coli (Apc) tumor suppressor, with multiple colonic tumors arising early in life, subsequent to loss of the remaining Apc allele. The most widely used mouse model of FAP is the ApcMin mouse (Moser et al. 1990), which also carries a germline mutation in Apc. However, unlike FAP patients, the ApcMin mouse develops mostly intestinal (rather than colonic) tumors of low grade, subsequent to loss of the remaining Apc allele. In the model developed by Powell et al. (Lrig1-CreERT2/+; Apcfl/+), one copy of Apc is inducibly eliminated in Lrig1-positive (presumably stem/progenitor) cells, precipitating rapid pre-neoplastic changes, with multiple, high-grade distal colonic adenomas developing subsequent to LOH of Apc (as early as 50 days). In other available models, including the LGR5-positive model (Barker et al. 2009), simultaneous rather than stepwise loss of Apc is required for tumorigenesis, which does not reflect the human disease. Moreover, the Lrig1-CreERT2/+; Apcfl/+ model shows some of the additional features of FAP, including highly penetrant perianpillary tumors, gastric dysplasia and hyperplasia, and lesions reminiscent of congenital hypertrophy of the retinal pigment epithelium (CHRPE), present in the majority of FAP patients.

**Lrig1 in the lung**

Given the prominent role of EGFR in human lung cancer (Siegelin & Borczuk 2014), Lu et al. (2013) examined the impact of LRG1 deletion on airway homeostasis. In the mouse, LRG1 is expressed in the epithelium of the trachea and the first few bronchial divisions. In Lrig1-null mice (Suzuki et al. 2002, neo/neo), proliferation of tracheal and bronchial epithelium was increased, accompanied by increased phospho-EGFR staining, providing another in vivo link between LRIG1 and EGFR. This reciprocal relationship between LRIG1 and EGFR was also observed in human lung cancer specimens, as has been discussed earlier (LRIG1 expression in cancer). In murine tracheal epithelial cell (MTEC) air–liquid interface cultures, proliferation of wild-type and Lrig1-null cells was similar in pre-confluent cultures; however post-confluence, Lrig1-null cells had a significant growth advantage, again accompanied by increased EGFR activation. Ectopic expression of LRIG1 in human A549 and H357 lung cancer cell lines, which express little endogenous LRIG1, significantly decreased cell proliferation post-confluence but not pre-confluence. LRIG1-mediated growth inhibition of H357 tumor cells was recapitulated in vivo, in subcutaneous xenografts, in which only one of 11 mice (9%) developed tumors from LRIG1 transduced cells while nine of ten mice (90%) developed tumors from the control group. The mechanism by which LRIG1 regulates cell contact-mediated growth inhibition is likely to be related to its ability to promote interaction between EGFR and E-cadherin. This EGFR–E-cadherin interaction was previously found to inhibit ligand-dependent activation of EGFR (Qian et al. 2004), and the present work from Lu et al. reveals a ternary complex containing EGFR/LRIG1/ E-cadherin. The presumption is that LRIG1 is an essential mediator of the EGFR–E-cadherin interaction at sites of cell–cell contact, but further study is necessary.

**Lrig1 in the eye**

Recently, gene expression profiling of human corneal keratinocytes demonstrated that LRIG1 is highly expressed in corneal epithelial stem cells (Nakamura et al. 2014), adding to an expanding list of LRIG1-positive stem cells. Analysis of Lrig1-null mice (Suzuki et al. 2002, neo/neo) revealed thickened and keratinized corneal epithelium with rampant inflammation of the corneal stroma, beginning at 6 months of age and manifesting in 70% of mice by 24 months of age. Corneal epithelial cells in Lrig1-null mice were more proliferative and showed evidence of a change in cell fate, from corneal to keratinized epithelium. Time-dependent analysis of recovery from corneal wounding (which depends upon the integrity of corneal stem cells) demonstrated a deficit in Lrig1-null mice with incomplete wound healing.
Endocrine-Related Cancer

Lrig1 expression of constitutively active STAT3 in the basal layer was exacerbated by corneal wounding. Finally, transgenic Lrig1 cytokines were up-regulated in wild-type tissue. Furthermore, a number of inflammatory cytokines were up-regulated in Lrig1-null tissue and this was exacerbated by corneal wounding. Finally, transgenic expression of constitutively active STAT3 in the basal layer of the epithelium recapitulated the Lrig1-null phenotype while inhibition of STAT3 with the small molecule STA21 prevented wound-induced corneal opacity in Lrig1-null mice, cementing the STAT3 pathway as a target of LRG1. Bone marrow transplantation experiments demonstrated that wild-type bone marrow reduced the severity of the wound-induced phenotype, demonstrating a cooperation between Lrig1-null bone marrow and corneal tissue. The mechanism by which LRG1 regulates the STAT3 pathway is presently unknown. Analysis of other tissue types in Lrig2-null mice may reveal whether STAT3 regulation by LRG1 is restricted to the cornea or is a more widespread mechanism.

Lrig2-null mice

Recently, the generation of Lrig2-null mice was reported (Rondahl et al. 2013). Lrig2-null mice showed increased mortality compared with heterozygous and wild-type mice, although the underlying mechanisms are not yet understood. Although embryo and birth weights were not different, null mice were found to be significantly smaller than heterozygous and wild-type mice by 5 days of age and these differences persisted until 12 and 15 weeks of age for females and males respectively. Given the previous finding that LRG2 is associated with decreased survival in human oligodendroglioma (Holmlund et al. 2009), the impact of LRG2 status on oligodendroglioma genesis in vivo was examined. In this study, a platelet-derived growth factor-B (PDGF-B)-driven model was used. Briefly, Ntv-a transgenic mice (which express the Tα avian retrovirus receptor under the control of the neural-specific nestin promoter) were generated on a wild-type, heterozygous, or Lrig2-null background. DF-1 cells producing PDGF-B-encoding retrovirus were then injected intracranially and tumor formation was analyzed. In the wild-type setting, 100% of injected mice developed brain tumors by 12 weeks of age (82% low grade, 18% high grade). In the Lrig2 heterozygous setting, 100% of injected mice developed tumors (92% low grade, 8% high grade) while in the Lrig2-null setting, only 77% of injected mice developed tumors by 12 weeks of age (100% low grade). Both tumor incidence and grade depended on Lrig2 genotype, uncovering a novel role of LRG2 in the promotion of PDGFB-driven brain tumor formation. Intriguingly, LRG2 had no apparent effect on the expression or phosphorylation of PDGF receptors (A or B) while ectopic expression of LRG1 was found to decrease PDGFRα expression. In addition, no effect of LRG2 was observed on phosphorylation of AKT or ERK1/2, signaling cascades which lie downstream from PDGFRα activation. However, the kinetics of immediate early gene expression following PDGF-B stimulation were altered in Lrig2-null mouse embryo fibroblasts (MEFs); expression of c-FOS and EGR2 peaked early and showed a more transient expression pattern. Given the complex interplay between signaling magnitude and duration in specifying cellular outcome (Kao et al. 2001), these changes in signaling kinetics could be functionally important. However, the mechanism by which LRG2 impacts PDGF signaling is unknown and does not appear to be at the level of the PDGFs.

LRG2 has also been found to impact EGFR signaling in human glioma cells (Wang et al. 2009), implying that it may make multifactorial contributions to brain tumor malignancy. Depletion of LRG2 in the GL15 glioblastoma cell line led to increased EGF-dependent EGFR turnover, decreased EGF-dependent EGFR phosphorylation, decreased cell growth, and increased apoptosis, suggesting that LRG2 plays a supportive role in EGFR signaling. However, LRG2 depletion also increased GL15 cell invasion in vitro, which was unexpected given its effects on EGFR. As invasion is the major barrier to complete surgical resection of brain tumors (which in theory, would be curative), this suggests that any therapeutic strategy involving LRGs must be approached carefully. On the other hand, LRG1 depletion in GL15 cells led to increased EGFR and AKT phosphorylation, increased expression of c-MYC, increased cell proliferation and invasion, and decreased apoptosis (Xie et al. 2013), suggesting that LRG1 may play a more ‘straight-forward’ tumor suppressor role in brain malignancy. Indeed, overexpression of LRG1 in U87MG-EGFRv3 (Stutz et al. 2008) and U251 (Ye et al. 2009, Mao et al. 2013) glioblastoma cells and H4 glioma cells (Ye et al. 2009) inhibited EGFR signaling and decreased cell proliferation and invasion. In U251 cells, overexpression of LRG1 inhibited growth in the subcutaneous xenografts of tumor cells (Mao et al. 2013).
Lrig3-null mice

In a search for regulators of inner ear morphogenesis using gene trap technology, Lrig3 was identified as essential for lateral canal development by Abraira et al. (2008). A precisely timed and appropriately localized fusion process drives canal development and in Lrig3-null mice (Lrig3\textsuperscript{lox}, C57Bl6 background), fusion occurs earlier and beyond normal boundaries compared with wild-type mice, leading to lateral canal truncation. This phenotype is also observed in mice in which Lrig3 is specifically deleted in the otic epithelium, further refining LRIG3’s role in canal development (Abraira et al. 2010). Expression of Netrin1, a secreted protein related to laminin and an axon guidance molecule (Arakawa 2004), is spatially expanded in Lrig3-null mice, demonstrating that one function of LRIG3 is to restrict Netrin1 expression to fusion plate-forming cells. In agreement with this, lowering of the gene dosage of Netrin1 rescued the Lrig3-null phenotype, restoring normal canal development in Lrig3-null/Netrin1-heterozygous mice. The mechanisms by which LRIG3 restricts Netrin1 expression are not presently known, although the authors hypothesize that LRIG3 ‘titrates’ the activity of a receptor tyrosine kinase (such as FGFR, known to be involved in inner ear development) which in turn, fine-tunes Netrin1 expression. ERBB receptors do not appear to be involved in the LRIG3 phenotype as disruption of Neuregulin signaling with a dominant-negative ERBB4 has no effect on inner ear development in chick embryos, despite strong expression of ERBB2/ERBB3 in otic epithelium (Abraira et al. 2010).

Double-null mice

Unlike Lrig3-null mice, inner ear development is morphologically normal in Lrig1 and Lrig2-null mice (Del Rio et al. 2013). However, in Lrig1/Lrig2 double-null mice (Lrig1\textsuperscript{−/−}; Lrig3\textsuperscript{−/−}, C57Bl6 background), inner ear development is more severely impacted than when Lrig3 is deleted alone. Loss of Lrig1 in Lrig3-null mice does not worsen the lateral canal phenotype discussed earlier (and indeed, LRIG1 is not co-expressed with LRIG3 in lateral canal epithelium) but does lead to worsened phenotypes in the sites of LRIG1/LRIG3 co-expression, suggesting a level of functional redundancy for these two Lrigs in the inner ear. For example, the utricle and saccule do not separate in double-null mice and the posterior canal is smaller. Of note, Lrig1/Lrig3 double-null mice die in utero or at birth and display defects in multiple tissues, suggesting LRIG1/LRIG3 redundancy in other tissues. Conversely, Lrig1/Lrig2 double-null mice (Lrig1\textsuperscript{−/−}; Lrig2\textsuperscript{−/−}) show no deficits in inner ear development despite overlapping expression, demonstrating that LRIG3 is sufficient to orchestrate proper development of inner ear.

With respect to auditory sensitivity, Lrig1 single-null mice (Lrig1\textsuperscript{−/−}) required sounds 30-fold more intense than wild-type animals to elicit a response while Lrig2 single-null (Lrig2\textsuperscript{−/−}) and Lrig3 single-null (Lrig3\textsuperscript{−/−}) mice responded normally (Del Rio et al. 2013). However, loss of Lrig2 exacerbated the Lrig1 auditory phenotype and raised the threshold for response. Functionally, LRIG1 was shown to be essential for the initial detection of sound while LRIG2 is required for the neuronal response to sound. Interestingly, cochlear morphology was normal in Lrig1/Lrig2 double-null mice but innervation was abnormal with sparser efferent innervation. Analysis of Lrig1/Lrig2 double-null mice was also complicated by early mortality, although a small percentage survived to adulthood.

Soluble LRIG1 as a therapeutic

Restoration of tumor suppressors to deficient tumor cells may represent a promising therapeutic strategy in cancer. For example, the p53 tumor suppressor is the most commonly mutated gene in cancer and as such, there is intense interest in strategies that would enable the restoration of wild-type p53 function. A variety of approaches are being employed to target the p53 axis and some are already in clinical trials, highlighting the potential of this approach (Hong et al. 2014). Delivery of tumor suppressor microRNAs (as mimetics) or suppression of oncogenic microRNAs (with antagonirs) represents another highly feasible strategy and holds great promise for personalized cancer therapy (Sethi et al. 2014).

The ectopic expression of full-length LRIG1 has been shown to inhibit the growth, motility, and/or invasion of a variety of tumor cells, in vitro and in vivo (Laederich et al. 2004, Shattuck et al. 2007, Miller et al. 2008, Stutz et al. 2008, Ye et al. 2009, Krig et al. 2011, Li et al. 2011, Thomasson et al. 2011, Wang et al. 2012, Chang et al. 2013, Lu et al. 2013, Qi et al. 2013), making its potential restoration to LRIG1-deficient tumors of great interest. However, the translational applications of expressing full-length LRIG1 are limited at this time due to its large size and membrane-bound nature. Nevertheless, the soluble extracellular domain of LRIG1 (sLRIG1), containing only the leucine-rich repeats (with their flanking caps) or a decorin fusion thereof, was found to inhibit the growth of EGFR-expressing A431 squamous carcinoma cells (high expressors) and HeLa cervical adenocarcinoma
cells (low expressors) (Goldoni et al. 2007). sLRIG1 was demonstrated to specifically bind to the EGFR and inhibit both ligand-independent (basal) and ligand-dependent EGFR phosphorylation. However, unlike full-length LRIG1, sLRIG1 did not stimulate receptor degradation.

The expression of a larger version of sLRIG1, containing the entire extracellular domain, was found to inhibit EGF-dependent FOS induction and cell proliferation in COS-7 cells (Yi et al. 2011). In this study, full-length LRIG1 was revealed to undergo proteolytic processing in COS-7 cells, yielding a predominant 100 kDa species, likely corresponding to the entire extracellular domain, and a less prominent 60 kDa species. The production of sLRIG1 in COS-7 cells was largely dependent upon the ADAM17 metalloprotease as it was significantly inhibited by the specific ADAM17 inhibitor, TAPI2. The expression of full-length LRIG1 in HPB-ALL leukemia cells also led to the production of a 100 kDa sLRIG1 species; in co-culture experiments, LRIG1-expressing HPB-ALL cells inhibited EGF signaling in COS-7 cells, in a manner dependent upon metalloprotease activity (i.e. LRIG1 shedding from HPB-ALL cells). Analysis of mouse (tail skin) and human (prostate, ileum, stomach, and skin) tissues detected the expression of a 60 kDa LRIG1 species, strongly suggesting that LRIG1 processing occurs in vivo. As reported in the Goldoni et al. study, sLRIG1 did not promote EGFR degradation.

A key study highlighting the translational utility of sLRIG1 was recently published by Johansson et al. (2013). Using cell encapsulation technology, which allows for stable and prolonged expression of recombinant proteins by cell-based ‘bioreactors’, the impact of sLRIG1 (entire extracellular domain) on growth of patient-derived, orthotopic glioblastoma xenografts was assessed. sLRIG1 significantly inhibited tumor growth in vivo, in a manner independent of EGFR expression level. sLRIG1 had a similar inhibitory effect on two patient-derived xenografts, which differed greatly in their EGFR expression level (one with EGFR gene amplification, one without EGFR amplification). This independence from EGFR expression level was also observed in the xenografts of U87 glioblastoma cells; sLRIG1 had a similar growth inhibitory effect on U87, U87-EGFR, and U87-EGFRv3 – an oncogenic form of EGFR frequently expressed in glioblastoma cells. This is in contrast to Goldoni et al., who reported that EGFR expression was necessary for sLRIG1’s inhibitory activity. In co-culture experiments of U87 cells with sLRIG1-expressing cells, sLRIG1 had no effect on total EGFR expression or EGFR cell surface expression (as expected) but also, did not decrease EGF-stimulated EGFR phosphorylation (somewhat unexpected given prior studies). However, sLRIG1 did inhibit EGF-stimulated MAP kinase activity, suggesting that it was impacting EGFR signaling and slowed cell cycle progression. Most notably, delivery of sLRIG1 to patient-derived tumors, which were first allowed to establish for 2 weeks, was effective in significantly prolonging survival (32% increase in survival in mice implanted with sLRIG1-producing cells). This finding is particularly important because any potential therapy must be effective in the setting of established tumors. These findings emphasize the potential of sLRIG1 as a therapeutic and also extend its likely utility beyond EGFR-overexpressing malignancies.

Beyond sLRIG1, therapeutic possibilities for LRIG1-deficient tumors include microRNA-based re-expression of LRIG1 and inhibition of pathways that are activated upon LRIG1 depletion. With respect to microRNAs, which regulate LRIG1, essentially nothing is known. LRIG1 was found to be under-expressed in chronic lymphocytic leukemia (CLL) patients who expressed low levels of MIR15a/16-1, although there was no molecular analysis conducted (Hanlon et al. 2009). With respect to pathways activated upon LRIG1 depletion, the MAP kinase inhibitor U1026 or the sphingosine kinase-1 inhibitor SK1-I was found to significantly inhibit the survival, migration, and invasion advantages of head and neck cancer cells in which LRIG1 was knocked down (Sheu et al. 2014). An obvious caveat to this approach is that LRIG1 depletion/loss may lead to the activation of multiple pathways which could not all be effectively inhibited clinically. Indeed, knockdown of LRIG1 in MDA-MB-231 breast cancer cells and SKOV-3 ovarian cancer cells leads to increased expression of multiple receptor tyrosine kinases, including MET and RON (Bai et al. 2012). On the other hand, tumors which retain LRIG1 expression may be particularly sensitive to certain therapeutics, opening a window of opportunity. For example, Smac mimetics, small molecules which are under clinical development, mimic endogenous Smac/DIABLO and inhibit the inhibitors of apoptosis (IAP) proteins cIAP1/2 and XIAP, triggering TGFA-dependent apoptosis. The requirement of LRIG1 expression for SM-164 (Smac mimetic)-induced TGFA expression and growth inhibition was shown in knockdown experiments (Bai et al. 2012). SM-164-resistant cells expressed low levels of LRIG1 and increased the levels of receptor tyrosine kinases. However, the mechanism by which LRIG1 regulates SM-164-induced TGFA expression is unknown. Sensitivity to SM-164 was restored by tyrosine kinase inhibitors which target multiple kinases, including GSK1363089 and PF2341066, suggesting that activation of
these kinase pathways (which would happen in a LRIG1-depleted setting) may suppress SM-164-mediated TGFA expression.

**LRIG mechanism of action**

A persistent area of controversy in the LRIG field regards the molecular mechanism(s) by which the LRIG proteins function. The first studies implicating LRIG1 as a negative regulator of ERBB receptor tyrosine kinases both found that LRIG1 enhanced receptor ubiquitination and proteolytic degradation (Gur et al. 2004, Laederich et al. 2004). Gur et al. delved deeper into the molecular mechanism and reported that LRIG1 recruits the c-CBL ubiquitin ligase to the EGFR–LRIG1 complex (via interaction of c-CBL with the LRIG1 cytoplasmic domain) and that c-CBL is functionally essential for LRIG1-mediated EGFR degradation. The authors proposed that LRIG1 evolved as a surrogate means of c-CBL recruitment. However, CBL70Z, a well characterized dominant negative form of c-CBL, was found to have no effect on LRIG1-mediated downregulation of EGFR and EGFRv3 (Stutz et al. 2008), suggesting that regulation of EGFR by LRIG1 is c-CBL independent. A subsequent study found that LRIG1-mediated MET destabilization is c-CBL independent (Shattuck et al. 2007), despite MET being a well-known target of c-CBL (Peschard et al. 2001). In support of this, it has been recently reported that the SAIT301 antibody promotes MET receptor degradation, in a LRIG1-dependent, c-CBL-independent manner (Lee et al. 2014). LRIG1 itself becomes ubiquitinated following SAIT301 treatment, promoting its interaction with hepatocyte growth factor-regulated tyrosine kinase substrate (HRS), which recognizes ubiquitinated cargo and facilitates sorting into multivesicular bodies for eventual lysosomal degradation (Oh et al. 2014). In this study, LRIG1 was found to promote lysosomal degradation of MET through interaction of the LRIG1–MET complex with HRS. Furthermore, LRIG1 was identified to be a target of the deubiquitinating enzyme USP8, which was shown to counteract LRIG1 ubiquitination and degradation. Interestingly, SAIT301 triggers LRIG1/MET degradation by interfering with LRIG1–USP8 interaction.

Recently, deletion analysis of LRIG1 has led to the finding that Δ-cyto LRIG1 (lacking the entire cytoplasmic domain which contains the c-CBL binding site) is fully active in the mediation of ERBB2 degradation (Rafidi et al. 2013), underscoring the existence of a c-CBL independent mechanism for LRIG1. This is supported by the prior finding that Δ-cyto LRIG1 and wild-type LRIG1 have similar abilities to inhibit the growth of glioma cells (Yi et al. 2011).

In light of these recent findings, the model of LRIG1 mechanism of action must be revised. Mounting evidence suggests that it is unlikely that LRIG1 functions in a c-CBL-dependent manner. Knockdown of LRIG1 has been found to increase the cell surface expression of EGFR (Jensen & Watt 2006), while ectopic expression of LRIG1 has been found to enhance the EGF-stimulated internalization of EGFR (Rafidi et al. 2013), strongly suggesting that LRIG1 does engage the receptor internalization machinery. Co-expression of LRIG1 with ERBB4 leads to their colocalization in intracellular vesicles, but the identity of these vesicles is unknown (Abaira et al. 2010). Furthermore, Sma-10, the C. elegans LRIG ortholog, is localized to intracellular puncta, possibly the endocytic vesicles (Gumienny et al. 2010). The ability of LRIG1 to enhance EGFR internalization depends upon its extracellular domain as the Δ-ecto mutant of LRIG1 was ineffective in the stimulation of EGFR internalization (Rafidi et al. 2013). This is not surprising as the extracellular domain is necessary for physical interaction with EGFR and other targets (Gur et al. 2004, Rafidi et al. 2013). However, the LRIG1 extracellular domain could conceivably interact with a third component which spans the membrane and engages the cytosolic receptor degradation machinery (Rafidi et al. 2013). This model does not contradict with the finding that Δ-cyto LRIG1 is as active as full-length LRIG1, while the c-CBL dependent mechanism does not explain the activity of Δ-cyto LRIG1. Recruitment of HRS to LRIG1 (Oh et al. 2014), which presumably occurs through HRS-mediated recognition of ubiquitinated residues in the LRIG1 cyto domain, also does not explain the activity of Δ-cyto LRIG1.

**Conclusion**

The study of LRIG proteins has spanned nearly two decades, with the initial cloning of mouse LRIG1 in 1996 (Suzuki et al. 1996). Tremendous knowledge has been gained through the concerted efforts of LRIG researchers, using in vitro and in vivo approaches. Most notably, LRIG1 has ‘arrived’ on the cancer biology scene as a tumor suppressor. The seminal hypothesis that LRIG1 is a functional homolog of Kekkon-1, a negative regulator of EGFR signaling in flies (Nilsson et al. 2001, Hedman et al. 2002, Suzuki et al. 2002), spurred the field forward and provided a molecular rationale for the pursuit of LRIG1.
(Gur et al. 2004, Laederich et al. 2004). While Lambik (rather than Kekkon-1) is now recognized as the Lrig ortholog in flies, LRIG1 and Kekkon-1 share functional attributes, including the ability to inhibit EGFR phosphorylation and signaling. In this sense, we have come full circle with LRIG1, from candidate regulator of EGFR/ERBB receptors to in vivo validated negative regulator of growth factor receptors, including EGFR/ERBB receptors. Learning more about Lambik function, of which nothing is known beyond its ability to rescue Sma10-mutant animals (Gumienny et al. 2010), should provide deeper insights into LRIG function. Many incredibly important questions linger in the LRIG field, both in developmental and cancer biology, and we look forward to their resolution in the years to come.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding

Salary support for the authors was provided by UC-MEXUS (M E C Prieto) and by NIH grant CA118384 (C Simion and C Sweeney).

References


Abraira VE, Satoh T, Fekete DM & Goodrich LV 2010 Vertebrate Lrig3–ErbB interactions occur in vitro but are unlikely to play a role in Lrig3-dependent inner ear morphogenesis. PLoS ONE 5 e8981. (doi:10.1371/journal.pone.0008981)


Jensen KB, Collins CA, Nascimento E, Tan DW, Frye M, Itami S & Watt FM 2009 Lrig1 expression defines a distinct multipotent stem cell


Roberts NA, Woolf AS, Stuart HM, Thuret R, McKenzie EA, Newman WG & Hilton EN. 2014 Heparanase 2, mutated in urofacial syndrome,


Received in final form 12 August 2014
Accepted 1 September 2014
Made available online as an Accepted Preprint 2 September 2014